Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.
Immutep Announced Tuesday, Data From Efti In Combination With Keytruda In First Line Head And Neck Squamous Cell Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study
Company Profile
Wed. 24 Apr 2024, 5:42am ET
Benzinga
News